Skip to content
Search

Latest Stories

'Gut bacteria may have a role in diabetes'

One type of bacteria found in the gut may contribute to the development of Type 2 diabetes, while another may protect from the disease, according to early results from an ongoing, prospective study led by investigators at Cedars-Sinai.

The study, published in the peer-reviewed journal Diabetes, found people with higher levels of a bacterium called Coprococcus tended to have higher insulin sensitivity, while those whose microbiomes had higher levels of the bacterium Flavonifractor tended to have lower insulin sensitivity.


Mark Goodarzi, the director of the Endocrine Genetics Laboratory at Cedars-Sinai in Los Angeles, California, is leading an ongoing study that is following and observing people at risk for diabetes to learn whether those with lower levels of these bacteria develop the disease.

"The big question we're hoping to address is: Did the microbiome differences cause diabetes, or did diabetes cause the microbiome differences?" said Goodarzi, who is the senior author of the study and principal investigator of the multicenter study called Microbiome and Insulin Longitudinal Evaluation Study (MILES).

Investigators involved in MILES have been collecting information from participating Black and non-Hispanic white adults between 40 and 80 years of age since 2018. An earlier cohort study from the MILES trial found that birth by cesarean section is associated with a higher risk of developing prediabetes and diabetes.

For the most recent study to come out of this ongoing trial, investigators analyzed data from 352 people without known diabetes who were recruited from the Wake Forest Baptist Health System in Winston-Salem, North Carolina.

Study participants were asked to attend three clinic visits and collect stool samples prior to the visits. Investigators analysed data collected at the first visit. They conducted genetic sequencing on the stool samples, for example, to study the participants' microbiomes, and specifically look for bacteria that earlier studies have found to be associated with insulin resistance.

Each participant also filled out a diet questionnaire and took an oral glucose tolerance test, which was used to determine the ability to process glucose.

Investigators found 28 people had oral glucose tolerance results that met the criteria for diabetes. They also found that 135 people had prediabetes, a condition in which a person's blood sugar levels are higher than normal but not high enough to meet the definition of diabetes.

The research team analysed associations between 36 butyrate-producing bacteria found in the stool samples and a person's ability to maintain normal levels of insulin. They controlled for factors that could also contribute to a person's diabetes risk, such as age, sex, body mass index and race.

Coprococcus and related bacteria formed a network of bacteria with beneficial effects on insulin sensitivity. Despite being a producer of butyrate, Flavonifractor was associated with insulin resistance; prior work by others have found higher levels of Flavonifractor in the stool of people with diabetes.

More For You

Omega Pharmacy in Derbyshire Finds New Owner in Just 18 Days

Omega Pharmacy

Christie & Co

Omega Pharmacy in Derbyshire sold in just 18 days

Omega Pharmacy in Derbyshire has found a new owner in less than three weeks after being put on the market.

The pharmacy was previously owned by husband-and-wife duo Manny and Poonam Rai, who decided to sell it after a short period of ownership to focus on their other pharmacy in Coventry, according to Christie & Co.

Keep ReadingShow less
DHSC announces second list of March 2025 price concessions

A price concession only applies for the month it is granted.

Getty Images

March price concessions list released; prescription charge remains unchanged

The Department of Health and Social Care (DHSC) has released a second list of price concessions for March 2025, following ongoing discussions with Community Pharmacy England (CPE) regarding medicine pricing concerns raised by pharmacy owners.

A price concession is introduced when pharmacy contractors are unable to source a drug at or below the reimbursement price set out in the Drug Tariff.

Keep ReadingShow less
AstraZeneca partners with CEPI to develop multi-specific influenza antibody

AstraZeneca-CEPI collaboration aims to increase global access to antibody-based interventions

Getty Images

AstraZeneca secures £33M CEPI funding to develop multi-specific influenza antibody

AstraZeneca has joined forces with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance an innovative antibody technology that could help tackle future infectious disease outbreaks and pandemics swiftly and more affordably.

CEPI will provide up to US$43.5 million (£33.6 million) in funding to support the biopharmaceutical company in evaluating a type of antibody, known as a VHH (Variable Heavy domain of a Heavy chain -only antibody), through preclinical proof-of-concept studies and Phase 1 clinical trials.

Keep ReadingShow less
Community Pharmacy Patient Safety Group announces new vice-chair

Martin Sadr-Kazemi 's appointment follows the passing of Dr. José Moss in January 2025.

Martin Sadr-Kazemi appointed vice-chair of Community Pharmacy Patient Safety Group

The Community Pharmacy Patient Safety Group (CPPSG) has announced the appointment of Martin Sadr-Kazemi as its new vice-chair.

Martin, currently the medication safety officer and deputy superintendent pharmacist at Rowlands Pharmacy, has been an integral member of the CPPSG since its formation a decade ago, actively contributing to various initiatives.

Keep ReadingShow less
"My work benefits all across London," says ambulance pharmacy technician

Mahrukh Jaffar

Pic credit: London Ambulance Service

"My work benefits all across London," says ambulance pharmacy technician

Mahrukh Jaffar will create history when she becomes the first apprentice to become a qualified pharmacy technician through the London Ambulance Service.

Jaffar is just days away from completing her registration with the General Pharmaceutical Council.

Keep ReadingShow less